Paracetamol
Drug1 gr
Other names: Perfalgan
NCT Number: NCT01422291
This randomized, controlled trial evaluates the analgesic efficacy and safety of intravenous single-dose paracetamol, dexketoprofen and morphine for the treatment of low back pain.
Looking for future studies?
Notify Me16 year–55 year
All sexes
Interventional
Phase 4
Study Design and Setting:
This is a single-center, prospective, randomized, double-blind, clinical trial performed in an ED of a tertiary care hospital with annual census of approximately 37.000 visits. The local ethics committee approved the study.
Interventions:
We conducted a randomized, controlled clinical trial comparing single intravenous doses of paracetamol (1 g), dexketoprofen (50 mg) and morphine (0.1 mg/kg) for patients presenting to the emergency department (ED) with suspected low back pain. Subjects with inadequate pain relief at 30 minutes received rescue fentanyl (0.75 microg/kg). We compared changes in pain intensity 30 minutes after treatment.
Methods of Measurements:
Subjects reported pain intensity on both a 100-mm visual analogue scale (limited by 'no pain' and 'the worst pain') and a 4-point verbal rating scale (no pain, mild, moderate, or severe pain) just before the drug administration, 15th minutes and 30th minutes after the study drug administration. The demographic features of study patients and adverse effects, nausea, vomiting, dizziness, vertigo, headache, hypotension, altered mental status, allergic reaction, itching, urinary retention, thoracic rigidity, respiratory depression and dry mouth, were recorded to the study form.
Outcome Measures The primary outcome measure was the pain reduction in VAS and VRS at 15th and 30th minutes. Secondary outcome measures were the need for rescue drug and the presence of any adverse event.
Primary Data Analysis:
The present study was planned as a superiority trial. When the 20 mm difference in VAS is accepted as clinically significant and the standard deviation is accepted as 25 mm, 35 patients are needed with each group with 95% power. All the analysis were implemented according to the intention to treat analysis. The precise of differences between time intervals within groups and between groups and statistical significance were expressed by 95% confidence intervals (95% CI).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 gr
Other names: Perfalgan
0.1mg/kg intravenous in 100 ml serum physiologic
Other names: Morphine CHL 0.01 gr
50 mg
Other names: Arveles
1 gr
Other names: Perfalgan
Time frame: 15 minutes interval
The pain of the study subjects was measured after 15th and 30th minutes later after the study drug administered
Time frame: 30 minutes after
30 minutes after the study drug administered
Pamukkale University
Other
Pamukkale University Medical School,Dept. of Emergency Medicine
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06840795
Back Pain, Low Back Pain
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06843785
Back Pain, Balance; Distorted
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06837753
Back Pain, Low Back Pain
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06787079
Back Pain, Behavior
Ankara, Turkey (Türkiye)
View Trial Details